Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

10.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

696
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
696
T Cell Types and Functions01:24

T Cell Types and Functions

3.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.1K
Inflammatory Response01:28

Inflammatory Response

18.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
18.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple Neurologic Deficits and Cognitive Decline in a Young Woman.

Annals of Indian Academy of Neurology·2019
Same author

Prediction model for successful radiocephalic arteriovenous fistula creation in patients with diabetic nephropathy.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia·2019
Same author

Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.

Nature reviews. Gastroenterology & hepatology·2019
Same author

IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis.

Scientific reports·2019
Same author

Spectroscopic and quantum computational study on naproxen sodium.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2019
Same author

Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease.

Hepatology international·2019
Same journal

The biological role of CCR4 and its ligands CCL17 and CCL22 in atopic dermatitis: therapeutic implications and future directions.

Expert opinion on therapeutic targets·2026
Same journal

Hepatocyte nuclear factor 4α - prospects for therapeutic targeting.

Expert opinion on therapeutic targets·2026
Same journal

The role of bile acid receptors in cholestatic liver disease: pathophysiological insights and therapeutic advances.

Expert opinion on therapeutic targets·2026
Same journal

Molecular insights for targeting the Nrf1 pathway in hepatocellular carcinoma.

Expert opinion on therapeutic targets·2026
Same journal

Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy.

Expert opinion on therapeutic targets·2026
Same journal

The AT<sub>2</sub> receptor as a potential target for autosomal dominant polycystic kidney disease therapy?

Expert opinion on therapeutic targets·2026
See all related articles

Related Experiment Video

Updated: Mar 14, 2026

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-&#947; Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

14.4K

Targeting IFN-λ: therapeutic implications.

Mohammed Eslam1, Jacob George1

  • 1a Storr Liver Centre, Westmead Institute for Medical Research , Westmead Hospital and University of Sydney , Sydney , Australia.

Expert Opinion on Therapeutic Targets
|September 30, 2016
PubMed
Summary
This summary is machine-generated.

Type-III interferons (IFN-λ) offer unique therapeutic potential for viral infections and cancers due to their distinct receptor complex and targeted tissue effects. Further research into IFN-λ characteristics promises novel treatment strategies with fewer side effects.

Keywords:
Interferon lambdaanti-viralcancerfibrosisinflammationtherapeutic

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K
An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

20.4K

Related Experiment Videos

Last Updated: Mar 14, 2026

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-&#947; Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

14.4K
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.9K
An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

20.4K

Area of Science:

  • Immunology
  • Virology
  • Oncology
  • Pharmacology

Background:

  • Type-III interferons (IFN-λ) are a recently discovered family with unique receptor complexes and tissue expression patterns compared to other interferons.
  • Polymorphisms near the IFNL3 gene are implicated in hepatitis C clearance and control, highlighting IFN-λ's role in viral infections.
  • IFN-λ exhibits antiviral, anti-tumor, immune-inflammatory, and homeostatic functions.

Purpose of the Study:

  • To summarize current and future therapeutic opportunities presented by Type-III interferons.
  • To explore the potential of IFN-λ as a therapeutic target for viral infections, cancer, and autoimmune diseases.

Main Methods:

  • Review of existing literature on Type-III interferons.
  • Analysis of genome-wide association studies (GWAS) and validation reports related to IFNL3.
  • Synthesis of current knowledge on IFN-λ's biological activities and therapeutic applications.

Main Results:

  • IFN-λ's unique characteristics, including its receptor complex and restricted tissue expression, make it an attractive therapeutic candidate.
  • Evidence suggests a role for IFN-λ in controlling epithelial cell-tropic viral infections.
  • Overlapping functions with Type I IFN, coupled with restricted expression, suggest potential for targeted therapies with limited side effects.

Conclusions:

  • Knowledge of IFN-λ is rapidly expanding, revealing significant therapeutic promise.
  • Despite remaining questions, the unique properties of IFN-λ support optimism for developing multiple novel therapeutic options.
  • IFN-λ represents a promising avenue for treating viral infections, cancers, and autoimmune diseases.